Senolytics and the Glaucoma Niche: Clearing Old Cells for Longer-Life Signals
Indeed, multiple studies have found senescence markers in RGCs and optic nerve tissue in glaucoma models. Notably, removing those old RGCs has been...
“senolytic”
Deep research and expert guides on maintaining your visual health.
“senolytic”
A “senolytic” is a kind of therapy that selectively removes worn-out cells that have stopped dividing but refuse to die. Normal cells stop dividing for many reasons, and sometimes they enter a state called senescence where they release inflammatory substances and alter tissue function. Senolytic treatments are designed to recognize features of those cells and trigger their death so healthier cells can take over. They work differently from drugs that simply suppress harmful signals; they aim to reduce the number of problem cells themselves. This approach matters because the buildup of senescent cells is linked to aging, chronic inflammation, and many diseases, so clearing them can restore tissue function and reduce symptoms. Early research shows benefits in animal models across a range of conditions, from joint disease to organ degeneration and loss of nerve function. But finding senolytics that are safe and specific is difficult, because killing cells in the wrong place or at the wrong time could cause harm. Scientists are exploring dosing schedules, delivery methods, and combinations with other treatments to get the best effect with the fewest risks. If successful, these therapies might slow aspects of aging, improve recovery after injury, and help treat diseases where old, harmful cells accumulate.